Virginia secures $12.6 billion in onshoring commitments as Trump pushes drugmakers to expand US manufacturing
The Commonwealth of Virginia is emerging as a leading destination for pharmaceutical manufacturing investments after recent policy encouragement from the White House.
President Donald Trump has urged drugmakers to increase their US manufacturing footprint, and three companies have pledged more than $12.6 billion in new projects in Virginia.
The announced projects include new API facilities such as AstraZeneca’s plant in Albemarle County, reflecting a broader trend of onshoring to reduce supply-chain risk.
State officials say the influx of capital positions Virginia as a competitive hub for drug production, potentially creating jobs and strengthening domestic supply.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Virginia leads in winning investments as drugmakers onshore to the US”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that